Clinical validation of a multi-modal Ataraxis AI platform for recurrence prediction in early-stage breast cancer across multiple patient cohorts.
Jan Witowski(Yara (Norway)), Lajos Pusztai(Yale University), Lina Daoud(The Barbara Ann Karmanos Cancer Institute), Frederick M. Howard(University of Chicago), Jailan A. Elayoubi(The Barbara Ann Karmanos Cancer Institute), Adam Brufsky(University of Pittsburgh), Irina Ostrovnaya(Memorial Sloan Kettering Cancer Center), Waleed Abdulsattar(The Barbara Ann Karmanos Cancer Institute), Freya Schnabel(New York University), Carlo Bifulco(Providence Health & Services), Arvydas Laurinavičius(Brigham and Women's Hospital), Elena Diana Chiru(Psychiatry Baselland), Nancy Chan(Unknown), Young-Joon Kang(Catholic University of Korea), Brian Piening(Providence College), Francisco J. Esteva(Northwell Health), Yu Zong(Wayne State University), Marcus Vetter(University Hospital of Basel), Jia Wern Pan(Cancer Research Malaysia), Khalil Choucair(The Barbara Ann Karmanos Cancer Institute)
Cited by 2
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k